Clinical Trial Update: To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of GDC-0449 in patients with Basal Cell Nevus Syndrome (Gorlin syndrome) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Nevus Syndrome
• Gorlin Syndrome

Drugs mentioned

• GDC-0449 (vismodegib)

Snippet

Sponsor: UCSF Benioff Children's Hospital Oakland | Conditions: Basal Cell Nevus Syndrome, Gorlin Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-01-11